HATCH/HARKIN BILL WARNING LETTER PROVISION DRAWS CRITICISM FROM FDA's
This article was originally published in The Tan Sheet
HATCH/HARKIN BILL WARNING LETTER PROVISION DRAWS CRITICISM FROM FDA's Mitchell Zeller, special assistant for policy in the agency's office of policy. Speaking at a Sept. 21 session of the Council for Responsible Nutrition's annual conference in Dana Point, Calif., Zeller declared that the Hatch/Harkin bill's provision allowing judicial review of FDA warning letters within 60 days of issuance "destroys the whole point of warning letters, which is to try to resolve a problem without going to court."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC